Chaohui Jin1, Hanrui Zheng1, Mei Zhan1, Feng Wen2,3, Ting Xu4. 1. Department of Clinical Pharmacy, West China Hospital, Sichuan University, Chengdu, China. 2. Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. 3. West China Biostatistics and Cost-Benefit Analysis Center, Sichuan University, Chengdu, China. 4. Department of Clinical Pharmacy, West China Hospital, Sichuan University, Chengdu, China. tingx2009@163.com.
Abstract
PURPOSE: A randomized phase III trial demonstrated that gemcitabine plus cisplatin (GP) prolonged progression-free survival and overall survival compared with fluorouracil plus cisplatin (FP) as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma (NPC). The cost-effectiveness analysis was designed to identify the economic option for metastatic NPC from a Chinese societal perspective. METHODS: We established a Markov model that involved three health states representing the stages of disease to simulate therapy. Survival data of clinical outcomes were derived from the trial and adjusted to quality-adjusted life years (QALYs). Transition probabilities and health utilities were obtained from the clinical trial and published literatures. The cost-effective strategy was estimated for these treatments using a willing-to-pay (WTP) threshold. A one-way sensitivity analysis was conducted to study the influences of parameters. RESULTS: GP treatment group produced a gain of 0.37 QALYs with an incremental cost of $2520.80, yielding an incremental cost-effectiveness ratio (ICER) of $6812.97 per QALY, compared with FP treatment ($15,530.96 versus $13,010.16). The ICER was lower than the accepted WTP threshold, which was 3 times gross domestic product per capita of China ($25,749 per QALY). CONCLUSION:GP regimen is more cost-effective compared with FP regimen as the first-line treatment for Chinese patients with metastatic NPC.
RCT Entities:
PURPOSE: A randomized phase III trial demonstrated that gemcitabine plus cisplatin (GP) prolonged progression-free survival and overall survival compared with fluorouracil plus cisplatin (FP) as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma (NPC). The cost-effectiveness analysis was designed to identify the economic option for metastatic NPC from a Chinese societal perspective. METHODS: We established a Markov model that involved three health states representing the stages of disease to simulate therapy. Survival data of clinical outcomes were derived from the trial and adjusted to quality-adjusted life years (QALYs). Transition probabilities and health utilities were obtained from the clinical trial and published literatures. The cost-effective strategy was estimated for these treatments using a willing-to-pay (WTP) threshold. A one-way sensitivity analysis was conducted to study the influences of parameters. RESULTS: GP treatment group produced a gain of 0.37 QALYs with an incremental cost of $2520.80, yielding an incremental cost-effectiveness ratio (ICER) of $6812.97 per QALY, compared with FP treatment ($15,530.96 versus $13,010.16). The ICER was lower than the accepted WTP threshold, which was 3 times gross domestic product per capita of China ($25,749 per QALY). CONCLUSION: GP regimen is more cost-effective compared with FP regimen as the first-line treatment for Chinese patients with metastatic NPC.
Authors: N L Liberato; C Rognoni; S Rubrichi; S Quaglini; M Marchetti; T Gorlia; L Licitra; J B Vermorken Journal: Ann Oncol Date: 2011-11-21 Impact factor: 32.976
Authors: Matthew C Ward; Chirag Shah; David J Adelstein; Jessica L Geiger; Jacob A Miller; Shlomo A Koyfman; Mendel E Singer Journal: Oral Oncol Date: 2017-09-23 Impact factor: 5.337
Authors: Malek B Hannouf; Chander Sehgal; Jeffrey Q Cao; Joseph D Mocanu; Eric Winquist; Gregory S Zaric Journal: PLoS One Date: 2012-06-20 Impact factor: 3.240